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Abstract Objective: To compare 
the cost and cost-effectiveness of a
policy of pre-operative optimisation
of oxygen delivery (using either ad-
renaline or dopexamine) to reduce
the risk associated with major elec-
tive surgery, in high-risk patients.
Methods: A cost-effectiveness analy-
sis using data from a randomised
controlled trial (RCT). In the RCT
138 patients undergoing major elec-
tive surgery were allocated to re-
ceive pre-operative optimisation em-
ploying either adrenaline or dopex-
amine (assigned randomly), or to re-
ceive routine peri-operative care.
Differential health service costs were
based on trial data on the number
and cause of hospital in-patient days
and the utilisation of health care re-
sources. These were costed using
unit costs from a UK hospital. The
cost-effectiveness analysis related
differential costs to differential life-
years during a 2year trial follow-up.
Results: The mean number of inpa-
patient days was 16 in the pre-
optimised groups (19 adrenaline; 
13 dopexamine) and 22 in the stan-
dard care group. The number (%) of
deaths, over a 2year follow-up, was
24 (26%) in the pre-optimised
groups and 15 (33%) in the standard
care group. The mean total costs
were EUR 11,310 in the pre-opti-
mised groups and EUR 16,965 in the
standard care group. Life-years were
1.68 in the pre-optimised groups and
1.46 in the standard care group. The
probability that pre-operative optimi-
sation is less costly than standard
care is 98%. The probability that it
dominates standard care is 93%.
Conclusions: Based on resource use
and effectiveness data collected in
the trial, pre-operative optimisation
of high-risk surgical patients under-
going major elective surgery is cost-
effective compared with standard
treatment.





Pre-operative optimisation employing 
dopexamine or adrenaline for patients 
undergoing major elective surgery: 
a cost-effectiveness analysis
Introduction
Clinical trials have shown pre-operative optimisation
(pre-op) to reduce the risk of complications and death in
high-risk patients undergoing major elective surgery 
[1, 2, 3]. There is also evidence that the use of pre-op re-
sults in reduced hospital costs [1, 2] and that it consti-
tutes a cost-effective method of managing high-risk sur-
gery [4]. However, these results have yet to have a major
influence on surgical management.
A recent trial of pre-op [3] compared standard peri-op-
erative patient management with pre-op in high-risk pa-
tients undergoing major elective surgery. In addition, the
trial assessed the relative performance of the inotropes –
adrenaline and dopexamine – given to enhance oxygen
delivery. The study randomised 138 patients to receive
standard management (n=46); pre-op employing adrena-
line (n=46) or pre-op employing dopexamine (n=46)
(Fig. 1). The results showed a significant reduction in
hospital mortality associated with pre-op (3%) compared
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with standard patient management (17%) and a reduction
in morbidity associated with pre-op employing dopexam-
ine (30%) compared with that employing adrenaline
(53%) and standard patient management (61%) [3]. 
In addition to the mortality and morbidity benefits,
the trial also found some important differences in re-
source consumption between the three arms. In particu-
lar, the use of dopexamine was associated with a signifi-
cantly shorter hospital stay [3].
This paper presents the results of a retrospective eco-
nomic analysis of that trial. The primary aim of the anal-
ysis was to determine the cost-effectiveness of pre-op
compared with standard patient management, from a
health service perspective, based upon mean cost and
mean effect differences. The secondary aims were to 
determine the cost-effectiveness of the inotropes used 
in the delivery of optimisation, to compare the three 
methods of pre-operative patient management and to es-
timate the probability that each method is the optimal
choice for the decision maker.
Fig. 1 Patient flows through
the study. Morbidity is defined
as the percent of patients devel-
oping one or more of a prede-
fined range of complications.
One patient (pre-op with adren-
aline, other abdominal sub-
group) was excluded from the
analysis due to the absence of
any data concerning resource
use
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Glossary of terms
Bayesian methods. Statistical framework which repre-
sents a learning process. As new information becomes
available, it is combined with initial beliefs (priors), us-
ing Bayes’ theorem, to provide an updated belief (poste-
rior) which is based on all information.
Cost-effectiveness analysis. Method of comparing alter-
native treatments in terms of their costs and health ef-
fects, with health effects measured in natural units (e.g.
life-years). Results are usually presented as an incremen-
tal cost-effectiveness ratio (ICER).
Cost-effective. A treatment is considered cost-effective,
compared to an alternative, if the additional cost per unit
of effect is considered worthwhile (i.e. ICER < willing-
ness to pay for health effects).
Cost-effectiveness acceptability curve. Graph illustrating
the probability that a treatment is the most cost-effective
over a range of values for the decision maker’s willing-
ness to pay for health effects.
Discounting. Process of converting costs incurred and
health effects received at different points in time to a
common present value. This is undertaken to reduce the
weight attached to future costs and health effects to re-
flect the time preference of individuals – that is, they
prefer things now rather than in the future.
Dominance. One treatment dominates its comparator if it
is associated with lower costs and greater health effects.
Incremental analysis. Analysis of the additional costs
and additional effects associated with a treatment of in-
terest, compared with the next best alternative treatment.
Incremental cost-effectiveness ratio (ICER). Ratio of the
incremental cost to incremental effect associated with a
treatment, when compared to the next best (non-domi-
nated) alternative treatment.
Optimal choice. The treatment which provides the maxi-
mum health effect, from the set of cost-effective treat-
ments, i.e. the most cost-effective. As the maximum
amount that the decision maker is willing to pay for
health effect alters the set of cost-effective treatments,
and the optimal choice may alter.
Prior. Initial, pre-experiment belief based upon informa-
tion available or opinion. For example, this may reflect
results from previous trials.
Posterior. Updated, post-experiment belief incorporating
new information, e.g. recent trial results. Posterior is de-
termined by combining original prior and new informa-
tion using Bayes’ theorem.
Vague prior. Formed with no reference to the available
information, in order to minimise the impact of the prior
on the posterior distribution so that inferences are unaf-
fected by information external to the current data. The
use of a vague prior enables the data to speak for itself.
Willing to pay for health effects (λ). Maximum amount
that the decision maker is prepared to pay for each unit
of additional health effect. This may represent the health
outcome forgone if a more costly treatment displaces
other health care programmes.
Methods
Trial design
The design, baseline characteristics and clinical results of the
study have been published elsewhere [3]. In brief, the trial includ-
ed patients undergoing major elective surgical procedures in gen-
eral surgery, vascular surgery or urology who had been identified
as being at high risk of developing peri-operative complications.
This prognosis was based upon surgical criteria or the presence of
coexisting medical conditions. Whilst it was not possible to blind
either patients or clinicians to the standard care versus pre-op sta-
tus, double-blinding was employed within the pre-op groups con-
cerning the actual inotrope received. The randomisation was strati-
fied by three surgical sub-groups: vascular surgery; surgery for up-
per gastrointestinal malignancy and other abdominal surgery
(which included patients from urology and general surgery). Of
the patients, 30% underwent vascular surgery, 20% had surgery
for an upper gastrointestinal malignancy and 50% had other ab-
dominal surgery [3]. See Fig. 1 for a summary of the patient flows
through the original study.
Patients within the pre-op groups were admitted to either an in-
tensive care or high dependency care unit at least 4 h prior to sur-
gery. They received haemodynamic monitoring, fluid optimisation
and inotrope optimisation (employing either adrenaline or dopex-
amine). The inotropic support was continued for 12–24 h post sur-
gery. Patients within the control arm of the trial received standard
peri-operative patient management, as determined by the surgeon
and anaesthetist. At hospital discharge, the mortality in the pre-op
groups was 3% compared with 17% in the standard management
group (p=0.007). There was a significant reduction in both mor-
bidity and length of hospital stay within the pre-op group that re-
ceived dopexamine (30% morbidity, 13 days per patient), com-
pared with both the adrenaline (53%, 19 days per patient) and
standard management (61%, 22 days per patient) groups.
Resource use measurement
The measurement of resource consumption of all patients in the
trial is central to the process of estimating the differential cost as-
sociated with pre-op compared to standard patient management,
and of pre-optimisation with dopexamine compared to adrenaline.
Detailed resource use data were not collected prospectively as part
of the original trial protocol, hence it was necessary to review, 
retrospectively, the trial case record forms and clinical notes to
identify each patient’s National Health Service resource use.
The study focused on two key areas of resource use that were
expected to affect cost differences: that employed during the initial
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hospital stay and that employed in the management of subsequent
related events. For the initial hospital stay, the resource use was
fully detailed in clinical notes. For each patient, data were collected
on the length and type of in-patient stay, and usage of drugs, inter-
ventions, infusions and investigations. Drugs that patients were
taking on admission, analgesics and drugs given to help patients
sleep were excluded from the resource use profile. For patients ran-
domised to pre-op, the resource use profile included the length of
the period of optimisation and the fluid employed in the process.
Some patients were re-admitted subsequent to the initial hospi-
talisation. Two independent clinicians, blinded to the initial ran-
domisation, assessed whether subsequent admissions were related
to the initial surgical procedure. For those that were, resource use
was measured at an aggregate level, based upon length of stay.
These data related to the period of 6 months following initial sur-
gery because, beyond this period, it is assumed that re-admissions
related to the original procedure would be minimal.
Valuing resource use
The cost of managing each individual patient was estimated by ap-
plying the relevant unit cost data to the detailed resource profile
compiled for each patient in the study. The unit costs were ob-
tained from a specific NHS hospital, in 1999–2000 prices. All
drugs, including any consumables required to administer them,
were based on the British National Formulary [5]. The costs for all
infusions, investigations and interventions included overheads and
all consumables required to administer them. Hotel costs for the
intensive care unit, the high dependency unit and the surgical ward
included fixed costs, staff costs, estate costs, overheads and the
cost of monitoring equipment. The costs of all other equipment
were converted into hourly rates, based on their purchase and re-
sale prices, annual maintenance cost, expected useful life and esti-
mated usage per annum. These were included separately on a per
patient basis [6]. The additional cost of optimisation was calculat-
ed for each patient in the adrenaline and dopexamine arms, using
patient-specific length of hospital stay and use of fluid, together
with use of drugs and disposables set by the study protocol.
Given that the aim of the study was to cost different methods
of pre-operative patient management, the cost of the original sur-
gery was excluded from the analysis. However, the cost of any
further surgery required to manage a complication or related event
was included. The cost of subsequent admissions related to initial
surgery was calculated on a per diem basis, using the cost of a
standard surgical ward including overheads, drugs, infusions, in-
terventions and investigations.
All costs have been translated from pounds sterling into euros
at an exchange rate of £1:EUR 1.631.
Cost-effectiveness analysis
Cost-effectiveness is assessed by relating the differential cost of
the alternative patient management strategies to their differential
effectiveness in terms of patient life-years measured during the tri-
al. One treatment can be defined as more cost-effective than its
comparator if any of the following conditions apply: (a) it is less
costly and more effective (dominance); (b) it is more costly and
more effective, and its additional cost per extra unit of effective-
ness is considered worth paying by decision makers and (c) it is
less costly and less effective and the additional cost per extra unit
of effectiveness of its comparator is not considered worth paying
by decision makers. Figure 2 shows the incremental cost-effec-
tiveness plane [7] on which the incremental cost and effects (sur-
vival) associated with the intervention of interest are plotted. The
plane is split into four quadrants by the origin (which represents
the treatment comparator). Quadrant II represents condition (a),
described above. Conditions (b) and (c) are represented within
quadrants I and III, respectively, with the line labelled λ determin-
ing the additional cost per unit of effect which the decision maker
considers worth paying. Hence, if the incremental cost and effect
of the intervention falls within the area which lies to the south-east
of the line labelled λ, it is cost-effective. The area to the north-
west of the line (including the whole of quadrant IV) represents
the situation where the intervention of interest would not be con-
sidered cost-effective with respect to the comparator.
Mean resource use data are presented (with standard devia-
tions), by study group, for the period of 6 months following initial
surgery. Mean costs (with standard deviations) are presented, by
study group, for hospitalisation (in each type of ward), drugs, in-
terventions, infusions, investigations, pre-op and related events. In
addition, the median cost and interquartile range are provided to
highlight any skewness in the cost distribution. The mean and
standard error, median and interquartile range are presented for the
total cost for each patient management strategy.
For the cost-effectiveness analysis, estimates of the mean sur-
vival duration in the three arms of the trial are required. This was
based upon the area between the survival curves over the 2 year
follow-up and involves censoring all surviving patients at 2 years.
Discounting has not been undertaken, due to the short-time horizon
over which the resource consumption and clinical events occur.
The economic analysis was undertaken using Bayesian 
methods, employing vague priors concerning the effectiveness and
cost of the different management strategies. This ensured that the
trial results had a larger influence upon the analysis than the prior
beliefs [8]. The Bayesian analysis involved repeat re-sampling
from the costs and life-year data of the trial (10,000 iterations), in
order to generate a posterior distribution of mean costs and mean
life-years for the different management routines. The means of
these distributions are used to determine the incremental cost-
effectiveness ratios (ICERs) associated with the different methods
of patient management. In addition, the distributions are used to
calculate the probability that each of the patient management meth-
ods is the optimal choice, subject to a range of possible maximum
values that a decision maker might be willing to pay for an addi-
tional life-year (λ) in this patient group. A cost-effectiveness ac-
ceptability curve is then presented, for each of the interventions, by
plotting these probabilities for the various values of λ [9, 10, 11].
The Bayesian analysis was undertaken using the WinBUGS
(Windows-based Bayesian Inference Using Gibbs Sampling) soft-
ware package, whilst the cost-effectiveness analysis was conduct-
ed within Excel.
Fig. 2 Incremental cost-effectiveness plane
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Results
Resource use
Table 1 gives a summary of the key resources use within
the alternative arms of the trial. One patient (pre-op with
adrenaline, other abdominal sub-group) was excluded
from the analysis due to the absence of any data concern-
ing resource use. Patients who received pre-op spent an
average (SD) of 16 days (12) in hospital at the time of
surgery (19 in the adrenaline group, 13 in the dopexam-
ine group) compared to 22 days (26) in the standard care
group. In addition, patients who received pre-op tended
to have lower usage of key resources (with those ran-
Fig. 3 Survival after surgery (proportion of the original study
population)
Fig. 4 a Cost-effectiveness
plane for pre-operative optimi-
sation (either inotrope) versus
standard treatment. b Cost-ef-
fectiveness plane for pre-opera-
tive optimisation with adrena-
line versus pre-operative op-
timisation with dopexamine
For Evaluation Only.
Copyright (c) by Foxit Software Company, 2004 - 2007
Edited by Foxit PDF Editor
Table 1 Details of the key resource use collected on patients (pre-op pre-operative optimisation, HDU high dependency unit, n/a not
applicable, TPN total parenteral nutrition)
Resource Standard Adrenaline Dopexamine Pre-op (either inotrope)
Mean Median Mean Median Mean Median Mean Median 
(SD) n (IQR) (SD) n (IQR) (SD) n (IQR) (SD) n (IQR)
Length of stay
Initial hospitalisation
Ward (h) 437.33 271.00 387.67 286.00 248.59 196.50 317.36 235.00 
(588.03) 44 (168.25, 379) (317.21) 45 (212, 401) (147.39) 45 (172.75, 285.75) (254.84) 90 (190, 313)
ICU (h) 66.91 0.00 42.91 0.00 35.57 0.00 39.20 0.00 
(137.49) 21 (0.00, 36.25) (97.94) 21 (0.00, 27) (93.03) 17 (0.00, 24.00) (95.03) 38 (0.00, 25.00)
HDU (h) 25.15 0.00 25.38 21.00 24.30 23.00 24.84 22.00 
(53.51) 21 (0.00, 27.75) (28.93) 33 (0.00, 25.00) (18.35) 36 (15.00, 30.50) (24.04) 69 (2.00, 26.50)
Total 529.39 323.00 455.96 311.00 308.46 249.00 381.40 287.00 
(624.71) 46 (216.25, 500.75) (363.17) 45 (239, 505) (194.30) 46 (211.25, 330) (298.09) 91 (213, 392)
Subsequent in-patient stay
Related to 0.70 0.00 3.18 0.00 0.11 0.00 1.63 0.00 
surgery (days) (3.10) 3 (0.00, 0.00) (11.63) 4 (0, 0) (0.74) 1 (0.00, 0.00) (8.29) 5 (0.00, 0.00)
Main drugs
Cefotaximine 10.33 6.50 9.52 9.00 8.11 7.00 8.90 8.00 
(1 g i.v.) (10.50) 18 (3.00, 15.00) (5.56) 23 (7.00, 14.50) (5.56) 18 (5.25, 11.00) (5.54) 41 (6.00, 12.00)
Fragmin 15.92 12.00 13.76 11.00 9.66 9.00 11.60 9.00 
(2500 IU (12.36) 38 (8.00, 20.00) (11.38) 37 (7.00, 15.00) (3.70) 41 (8.00, 12.00) (8.48) 78 (8.00, 13.00)
subcutaneously)
Metronidazole 11.65 11.50 8.29 9.00 9.20 7.00 ) 8.73 8.00 
(500 mg i.v.) (8.88) 20 (3.00, 17.25) (5.84) 21 (3.00, 12.00) (7.44) 20 (4.50, 12.25 (6.60) 41 (3.00, 12.00)
Main infusions
Blood (units) 5.25 3.00 5.57 2.00 3.62 2.00 4.53 2.00 
(7.15) 32 (2.00, 6.00) (12.27) 23 (2.00, 4.00) (3.28) 26 (1.25, 4.75) (8.69) 49 (2.00, 4.00)
Altracurium 2.00 (n/a) 1 2.00 n/a (n/a) 0 n/a n/a (n/a) 0 n/a n/a (n/a) 0 n/a 
(2.00, 2.00) (n/a, n/a) (n/a, (n/a, n/a) (n/a, n/a)
Albumin 4.5% 12.22 7.50 5.63 3.00 5.41 4.00 5.50 4.00 
(250 ml) (14.46) 18 (3.00, 15.00) (6.15) 19 (1.50, 7.00) (3.97) 27 (3.00, 8.00) (4.92) 46 (2.00, 8.00)
Platelets 8.00 8.00 5.50 5.50 3.50 3.50 4.50 5.00 
(n/a) 1 (8.00, 8.00) (2.12) 2 (4.75, 7.25) (3.54) 2 (2.25, 4.75) (2.65) 4 (3.25, 6.25)
Cryoprecipitate 4.00 4.00 10.00 10.00 4.00 4.00 7.00 7.00 
(2.83) 2 (3.00, 5.00) (n/a) 1 (10.00, 10.00) (n/a) 1 (4.00, 4.00) (4.24) 2 (5.50, 8.50)
Main investigations
Full blood 9.13 6.00 8.71 6.00 6.51 5.00 7.61 5.00 
count (8.25) 46 (3.00, 12.75) (8.32) 45 (4.00, 10.00) (4.92) 45 (3.00, 8.00) (6.89) 90 (3.00, 9.00)
Clotting 7.06 4.00 5.40 2.50 4.00 2.50 4.74 2.50 
studies (8.26) 34 (1.00, 9.00) (7.31) 40 (1.00, 5.25) (5.31) 36 (1.00, 4.00) (6.44) 76 (1.00, 4.00)
Cross match 3.70 2.00 3.23 2.00 2.48 2.00 2.85 2.00 
(4.48) 46 (2.00, 3.75) (4.92) 43 (1.00, 3.00) (2.03) 44 (1.00, 3.00) (3.75) 87 (1.00, 3.00)
Urea and 9.87 7.00 9.00 6.00 6.60 5.00 7.80 5.00 
electrolytes (8.77) 45 (4.00, 13.00) (8.87) 45 (3.00, 11.00) (5.17) 45 (3.00, 8.00) (7.32) 90 (3.00, 9.00)
Main interventions
Surgery (h) 2.67 2.50 3.67 4.00 2.75 2.50 3.14 3.00 
(0.82) 6 (2.00, 3.00) (0.58) 3 (3.50, 4.00) (0.96) 4 (2.00, 3.25) (0.90) 7 (2.50, 4.00)
Arterial blood 25.73 10.50 14.13 6.00 11.67 7.50 12.94 6.00 
gas (number (33.91) 26 (2.25, 36.75) (21.79) 32 (2.75, 11.00) (13.45) 30 (4.00, 13.75) (18.13) 62 (3.00, 11.00)
given)
TPN 9.25 11.00 6.50 5.00 8.50 8.50 7.00 5.00 
(4.86) 8 (4.00, 12.50) (3.15) 6 (4.25, 8.75) (9.19) 2 (5.25, 11.75) (4.47) 8 (4.00, 10.25)
Pre-operative optimisation
Length of stay n/a n/a 9.18 5.00 10.30 6.00 9.75 5.00 
(h) (n/a) n/a (n/a, n/a) (6.89) 45 (4.00, 16.00) (7.17) 46 (4.00, 17.75) (7.02) 91 (4.00, 17.00)
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domised to dopexamine having the lowest usage over-
all).
Costs
The unit costs of key resources are detailed in Table 2.
Table 3 details the estimated costs for the standard care
group and the pre-op patients, both for the entire group
and separately for each inotrope. The additional costs of
administering pre-op were more than offset by reduc-
tions in the costs of the initial in-patient stay and in the
costs of resources used in post-operative patient care.
The mean cost associated with patients receiving pre-op
was EUR 11,310 (EUR 13,820 adrenaline, EUR 9,247
dopexamine) whilst the mean cost for patients receiving
standard management was EUR 16,965.
Life expectancy
In the paper reporting the clinical results of the study [3],
an 8% lower absolute risk of in-hospital mortality was
reported in the pre-op groups at hospital discharge. At
2 years post-surgery, standard patient management is as-
sociated with a mortality of 33% (15 deaths) compared
with 26% in the pre-optimisation groups (24 deaths – 
11 adrenaline, 13 dopexamine) (see Figure 3). Translat-
ing 2 year mortality into mean survival duration gener-
ates 1.68 years post-surgery for patients in the pre-op
groups (1.74 – adrenaline, 1.62 – dopexamine), com-
pared with 1.46 for patients receiving standard care.
Cost-effectiveness
Figure 4a illustrates the simulated values of mean incre-
mental costs and life-years for the comparison between
pre-op (using either inotrope) and standard care. Each
point represents one simulation result of mean cost and
life-year difference. Pre-op (using either inotrope) domi-
nates standard patient management based upon the mean
of these points. On average, pre-op is both cheaper (sav-
ing of EUR 5,655) and more effective (additional life-
years of 0.22). The majority of the points are located be-
low the horizontal axis (negative incremental cost), indi-
cating that the probability that pre-op is cost-saving is
high (98%). In addition, a considerable proportion of the
points are located within quadrant II, where pre-op in-
volves both reduced costs and higher survival duration
than standard care, indicating a considerable probability
that pre-op dominates standard patient management
(93%).
Figure 4b illustrates the simulated values of mean in-
cremental cost and effect for the comparison between the
inotropes. The majority of the points are located within
quadrant I, where adrenaline involves higher costs and
higher survival duration than dopexamine. Based upon
the mean of these points, pre-op employing adrenaline is
associated with an ICER of EUR 38,108 per life-year
gained when compared to pre-op employing dopexamine
(incremental cost = EUR 4,573; incremental effect
=0.12 life-years).
Figure 5a illustrates the probability that pre-op (using
either inotrope) is the optimal choice, compared with
standard patient management, for a range of maximum
values that a decision maker might be willing to pay for
an additional life-year (λ). The figure shows that the
probability that pre-op is optimal when the decision
maker is unwilling to pay anything for an additional life-
year (i.e. the probability that it is less costly than stan-
dard care) is 98%. If the decision maker is willing to pay
EUR 32,620 (£20,000) per life-year gained, the probabil-
ity that pre-op is optimal is 99.35%, hence the probabili-
ty that standard patient management is optimal is 0.65%.
Table 2 Unit costs of the key resources used within the trial (see
text for source of data) (ICU intensive care unit, HDU high depen-
dency unit, TPN total parenteral nutrition)
Resource Unit cost (euros)
Length of stay
Ward (per h) 16.80
ICU (per h) 57.90
HDU (per h) 41.59
Related stay (per day) 419.17
Main drugs (per dose)
Cefotaximine (1 g i.v.) 11.43
Fragmin (250 IU subcutaneously) 3.73
Metronidazole (500 mg i.v.) 8.46
Main infusions
Blood (per unit) 130.14
Altracurium infusion (ml/h) 58.96
Albumin 4.5% (250 ml per dose) 34.14
Platelets (per unit) 231.49
Cryoprecipitate (per unit) 39.36
Main investigations (per test)
Full blood count 6.61
Clotting studies 11.87
Cross match 14.22
Urea and electrolytes 5.76
Main interventions
Surgery (h) 631.20
Arterial blood gas 11.60
TPN 100.16
Pre-operative optimisation
Adrenaline (per patient) 390.07
Dopexamine (per patient) 130.02
Hotel costs (per hour) 1.80
Disposables (per patient) 3.83
Cost of fluid (per unit) 32.51
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This value is consistent with funding decisions made in
the UK NHS (for example by the National Institute for
Clinical Excellence).
Figure 5b compares all three patient management strat-
egies, illustrating the probability that each is the optimal
choice, for a range of λ values. When the decision maker
is unwilling to pay anything for an additional life-year, the
probability that pre-op with dopexamine is optimal (i.e.
dopexamine is cost-saving) is 99.6%. If the decision mak-
er is willing to pay EUR 32,620 (£20,000) per life-year
gained, the probability that pre-op with dopexamine is op-
timal is 57.2%, compared with probabilities of 42.6% and
0.2% for pre-op with adrenaline and standard patient man-
agement, respectively. Further discussion of the results of
the analysis, in particular the choice between adrenaline
and dopexamine, appears within the discussion section.
Discussion
The analysis presented here suggests that we expect 
pre-op to dominate standard management (probability
Fig. 5 a Cost-effectiveness ac-
ceptability curve showing the
probability that pre-operative
optimisation (either inotrope) is
optimal, compared with stan-
dard patient management, for a
given willingness to pay for an
additional life-year (λ). b Cost-
effectiveness acceptability
curves showing the probability
that each management option is
optimal for a given willingness
to pay for an additional life-
year (λ)
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93%). In addition, regardless of the value placed upon a
life-year gained, the probability of pre-op being optimal,
compared with standard care, is high (>97%). Hence, the
decision maker should choose to adopt pre-op for these
patients. However, this comparison does not inform the
decision maker as to which inotrope to employ within
the optimisation process and so decision makers will be
interested in a comparison of the three methods of pa-
tient management. For this comparison, we expect stan-
dard management to be dominated by both pre-op man-
agement strategies, with pre-op employing adrenaline
being more effective and expensive than pre-op employ-
ing dopexamine (with each additional life-year costing
EUR 38,108 – £23,367). In this situation, the decision as
to which method of patient management to employ and
the probability that this method is optimal, depends cru-
cially on the value that the decision maker is willing to
pay for additional life-years in this patient group.
If decision makers are only interested in costs, and
they do not value improvement in patients’ life expectan-
cy, they should adopt pre-op employing dopexamine
(probability of there being a cost-saving >99%). Howev-
er, we know that decision makers do value additional
life-years, and while no monetary value for incremental
health gain has officially been stated in the UK, values
of between Can$20,000 (EUR 14,385) and Can$100,000
(EUR 71,927) per quality-adjusted life-year gained were
suggested in Canada in 1992 [12]. Further, the National
Health Service has funded many interventions with im-
plied values within this range. For example, implantable
cardioverter defibrillators had an estimated cost per life-
year gained of £26,000–30,000 (EUR 42,400–48,930),
and was recommended for use by the National Institute
for Clinical Excellence [13].
The analysis shown in Fig. 5b indicates that if deci-
sion makers value additional life-years at a minimum of
EUR 32,620, they should adopt pre-op employing dop-
examine. At this value of λ the probability that this is the
optimal choice falls to 57%. This reflects the fact that as
decision makers are willing to pay more for a life-year
gained, pre-op employing adrenaline (which is both
more expensive and more effective than dopexamine)
becomes more attractive to them. That is, the additional
effects are considered worth the additional costs. On the
other hand, if the maximum willingness-to-pay for addi-
tional life-years exceeds EUR 38,108, the decision mak-
er should adopt pre-op employing adrenaline, with a
probability that this is the optimal choice of at least 50%.
The results of our study corroborate the cost and cost-
effectiveness analyses undertaken in previous studies [1,
14]. Shoemaker [1] concluded that average hospital
charges and patient expenditures were reduced for pa-
Table 3 Costs in the trial groups – euros (ICU intensive care unit, HDU high dependency unit)
Resource Standard Adrenaline Dopexamine Pre-op (either inotrope)
Mean Median Mean Median Mean Median Mean Median 
(SE) (IQR) (SE) (IQR) (SE) (IQR) (SE) (IQR)
Length of stay
Ward 7347 4553 6513 4805 4176 3301 5331 3948 
(9879) (2826, 6367) (5329) (3561, 6737) (2476) (2902, 4800) (4281) (3192, 5258)
ICU 3874 0 (0, 2099) 2485 0 (0, 1563) 2059 0 (0, 1390) 2270 0 (0, 1448)
(7960) (5671) (5386) (5502)
HDU 1046 0 (0, 1154) 1055 873 1011 957 1033 915 
(2225) (1203) (0, 1040) (763) (624, 1269) (1000) (83, 1102)
Total excluding 12267 7197 10053 6624 7246 5499 8634 5861 
related (13579) (3978, 13156) (9188) (4822, 10541) (6621) (4107, 7614) (8074) (4299, 9083)
Related 606 0 (0, 0) 1332 0 (0, 0) 46 (309) 0 (0, 0) 682 0 (0, 0)
in-patient stay (3380) (4875) (3477)
All drugs 367 169 243 126 215 103 229 115 
(496) (62, 470) (307) (51, 255) (296) (60, 240) (300) (52, 252)
All infusions 1124 400 777 256 611 296 693 287 
(1989) (162, 1100) (1888) (99, 551) (984) (76, 546) (1495) (98, 557)
All investigations 416 268 344 211 244 173 293 184 
(419) (125, 552) (380) (118, 327) (221) (128, 279) (312) (125, 320)
All interventions 856 90 474 46 337 52 405 46 
(1762) (0, 1008) (1073) (12, 293) (855) (0, 131) (966) (0, 206)
Pre-optimisation n/a (n/a) n/a 770 699 839 751 805 701 
(n/a, n/a) (250) (537, 1013) (267) (603, 1086) (260) (573, 1033)
Total cost 16,965 16,440 13,820 13,638 9,247 9,171 11,310 11,236 
(3,338) (14,640, 18,675) (1,743) (12,603, 14,823) (847) (8,667, 9,758) (889) (10,686, 11,856)
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tients receiving pre-op, but did not undertake a formal
cost-effectiveness analysis. Guest et al. [4] provided a
detailed analysis of the cost of resources associated with
pre-operative optimisation and standard patient manage-
ment pre-operatively, intra-operatively, post-operatively
and employed in treating complications. They concluded
that the median cost per patient and per survivor was
lower for the group receiving pre-op [4]. However, the
use of medians rather than means reduces the impact of
any extreme values on the results, and where data are
likely to be highly skewed (as costs typically are) the use
of medians will not facilitate an estimate of the total cost
impact across a sample of patients [14] In addition, the
use of the number of survivors, at 28 days post-surgery,
as the measure of effectiveness limits the analysis
through the implicit assumption that life expectancy for
survivors is identical between the groups. Our study has
attempted to capture the life-years gained associated
with pre-op patient management through the survival du-
ration data. However, the survival duration data has been
censored at 2 years post-surgery and so underestimates
the life expectancy of patients in all of the different pa-
tient management arms.
There are other limitations to this study. First, it con-
centrates upon the health care costs that directly affect
the hospital, and ignores costs that fall upon other sec-
tors, either directly or indirectly. For example, earlier
discharge from hospital may impact upon resource use at
a general practitioner or patient level, as patients receive
care at home rather than in hospital. Second, the study
utilised local costs applicable in one centre that may not
be representative of costs at other UK hospitals. Hence,
the study may not be generalisable to other settings with-
out some modification. Third, retrospective collection of
resource data can be a limitation to studies. However, in
this study the patient notes had been well maintained and
over 70% of the costs related to in-patient stay, about
which hospital information systems are generally accu-
rate and complete.
This study has shown that decision makers can be
confident that pre-op is a cost-effective method of man-
aging high-risk surgical patients undergoing major elec-
tive surgery. The study has also shown that, given cur-
rent levels of information, the decision concerning which
inotrope to employ, to achieve optimisation, depends
crucially upon the value that the decision maker is will-
ing to pay for additional life-years in this patient group.
In addition, there is considerable uncertainty surrounding
the choice between inotropes and further research is like-
ly to be good value for money.
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